Precision Medicine in the Management of Heart Transplant Recipients

Precision Medicine in the Management of the Heart Transplant Patient: Advanced Molecular and Imaging Approaches

The goal of this clinical trial is to demonstrate that a multiparametric approach, based on the integration of biomolecular, histological, imaging, and clinical information, along with the use of machine learning methods, can identify among heart transplant patients those at higher risk of rejection, infectious events, and chronic graft dysfunction.

Patients have been and will be treated according to clinical practice, in accordance with the physician's judgment and the information provided in the Technical Data Sheet of each individual product used in concomitant therapies, if administered according to clinical practice. The diagnostic-therapeutic pathway of the patients will not be in any way influenced by the results of tissue tests performed for the purposes of the study

Study Overview

• Status: Recruiting
• Conditions: Heart Transplantation

Detailed Description

The main focus of the study, and the primary outcome measure, is the diagnosis of rejection based on the histopathological examination of myocardial biopsies. At the time of each biopsy procedure, or within the 5 days immediately preceding, enrolled patients will undergo specific non-invasive investigations, along with baseline clinical and laboratory evaluations.

Additional analyses will be performed on myocardial tissue samples obtained during biopsies conducted for clinical practice, including the analysis of the intramyocardial gene expression profile (nanostring and microarray), to identify molecular profiles specific to cellular or antibody-mediated rejection.

The results of these investigations will be correlated with the findings from histopathological and molecular analyses of the biopsies using artificial intelligence methods, in order to develop a non-invasive investigation algorithm that can predict the risk of rejection.

Similarly, these diagnostic investigations will be longitudinally related to the incidence of infection events, as defined above, and to the development of myocardial fibrosis diagnosed by cardiac magnetic resonance imaging.

In a subsequent phase, biopsies will be reclassified through the examination of histopathological morphology using machine learning techniques. The result of the re-evaluation of the histological samples will be correlated with the diagnosis based on the intramyocardial gene expression and the predictiveness of the previously developed algorithm.

• Study Type: Observational
• Enrollment (Estimated): 200

Contacts and Locations

• Study Contact: Name: Luciano Potena, MD; Phone Number: 0512143725; Email: scompenso.trapiantocuore@aosp.bo.it

Study Locations

• Italy
  • Bologna, Italy, 40138
    • Recruiting
    • Luciano
    • Contact: Luciano Potena, MD; Phone Number: 0512143725; Email: scompenso.trapiantocuore@aosp.bo.it

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All adult patients undergoing orthotopic heart transplantation, attending the SSD Heart Failure and Transplants unit of the IRCCS Azienda Ospedaliero-Universitaria di Bologna, will be enrolled from 01/02/2023 to 31/12/2027. Each patient will be followed according to standard clinical care practices; the minimum follow-up for each patient will be 6 months.

Description

Inclusion Criteria:

• Age ≥ 18 years
• Have received an orthotopic heart transplant
• Clinical indication for performing a myocardial biopsy (either as part of standard monitoring or for suspected rejection)
• Obtaining informed consent

Exclusion Criteria:

• Severe complications in the post-operative phase that may limit the patient's short-term survival.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Histological diagnosis of rejection leading to a change in immunosuppressive therapy according to clinical practice.	Histological diagnosis	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Symptomatic infection requiring treatment with antimicrobial drugs	Infection from SARS-CoV-2 is excluded from this endpoint and will be analyzed separately	5 years
Development of myocardial fibrosis diagnosed on cardiac MRI	myocardial fibrosis diagnosis	5 years
Hospitalization for any cause.	Hospitalization	5 years
Mortality from any cause.	Mortality	5 years

Collaborators and Investigators

• Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Investigators: Principal Investigator: Luciano G Potena, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Study record dates

Study Major Dates

• Study Start (Actual): September 4, 2023
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: January 9, 2025
• First Submitted That Met QC Criteria: January 9, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 9, 2025
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: Precision-HT; RC-2022-2773280 (Other Grant/Funding Number: Bando RC 2022-2024, Ministero della Salute)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No